Ginkgo Q3 total rev $89M (+61% YoY) includes $45M deferred release; core $44M (-21%); guides FY $215-235M

Ginkgo Bioworks Holdings, Inc.

2024-Q3 EPS reported -$8.58 revenue$183,196,000

Total revenue $89M (+61% YoY) incl. $45M non-cash deferred revenue; core rev $44M (-21%).
Cell Engineering ex-deferred $30M (-20% YoY); Biosecurity $14M with 28% gross margin.
Loss from ops $(55)M vs $(286)M; Adj EBITDA $(20)M vs $(84)M.
FY24 guidance raised: Total rev $215-235M, Cell Eng $165-185M, Biosecurity ≥$50M.
Appointed Dr. Sri Kosuri to Board; Dr. Belldegrun resigned. Signed deal with Novo Nordisk; Merck milestone $9M.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Arie Belldegrun

Director

DNA · Ginkgo Bioworks Holdings, Inc.

Effective: 2024-11-07
Filed: November 12, 2024, 6:59 PM ET

On November 7, 2024, Dr. Arie Belldegrun resigned from his position as a director of the Board.

Appointed

Dr. Sri Kosuri

Class B Director

DNA · Ginkgo Bioworks Holdings, Inc.

Effective: 2024-11-06
Filed: November 12, 2024, 6:59 PM ET

On November 6, 2024, the Class B directors of the board of directors (the “Board”) of the Company appointed Dr. Sri Kosuri to the Board as a Class B director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Arie Belldegrun resigned as Director at Ginkgo Bioworks Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On November 7, 2024, Dr. Arie Belldegrun resigned from his position as a director of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Sri Kosuri was appointed as Class B Director at Ginkgo Bioworks Holdings, Inc..

Action: appointed
Role: Class B Director

Exact text from the filing

On November 6, 2024, the Class B directors of the board of directors (the “Board”) of the Company appointed Dr. Sri Kosuri to the Board as a Class B director.

View on SEC.gov

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-047276

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.